PharmaCorp Rx (TSXV:PCRX) EV-to-EBIT : -36.13 (As of Jun. 01, 2025)

PharmaCorp Rx EV-to-EBIT Chart

PharmaCorp Rx Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial									-13.23	-10.47	0.41	-27.70	-45.09

Competitive Comparison of PharmaCorp Rx's EV-to-EBIT

For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCorp Rx's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmaCorp Rx's EV-to-EBIT falls into.

PharmaCorp Rx EV-to-EBIT Calculation

PharmaCorp Rx's EV-to-EBIT for today is calculated as:

PharmaCorp Rx's current Enterprise Value is C$41.48 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx  (TSXV:PCRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PharmaCorp Rx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

PharmaCorp Rx's Enterprise Value for the quarter that ended in Dec. 2024 was C$50.72 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PharmaCorp Rx's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCorp Rx Business Description